187805-54-5

Basic information

• Product Name: Benzamide, 2-amino-3-fluoro- (9CI)
• Synonyms: Benzamide, 2-amino-3-fluoro- (9CI);2-aMino-3-fluorobenzaMide
• CAS NO: 187805-54-5
• Molecular Formula: C₇H₇FN₂O
• Molecular Weight: 154.1416832
• Product Categories: HALIDE;AMIDE
• Mol File: 187805-54-5.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Benzamide, 2-amino-3-fluoro- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Benzamide, 2-amino-3-fluoro- (9CI)(187805-54-5)
• EPA Substance Registry System: Benzamide, 2-amino-3-fluoro- (9CI)(187805-54-5)

Safety Data

• Hazardous Substances Data: 187805-54-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
Benzamide, 2-amino-3-fluoro(9CI) is used as a pharmaceutical intermediate for the development of various biologically active molecules. Its unique structure and properties contribute to the creation of new drugs with potential therapeutic applications.
Used in Organic Synthesis:
In the field of organic synthesis, Benzamide, 2-amino-3-fluoro(9CI) serves as a building block for synthesizing a wide range of compounds with diverse chemical and biological properties. Its versatility as a synthetic precursor is highly valued in the chemical industry.
Used in Enzyme Inhibition Studies:
Benzamide, 2-amino-3-fluoro(9CI) has been studied as a potential inhibitor of certain enzymes. Its ability to modulate enzyme activity makes it a candidate for the development of drugs targeting specific enzymatic pathways in various diseases.
Used in Medicinal Chemistry for Fluorine Incorporation:
As a source of fluorine, Benzamide, 2-amino-3-fluoro(9CI) is utilized in medicinal chemistry to incorporate fluorine atoms into drug molecules. The presence of fluorine can significantly alter the pharmacokinetic and pharmacodynamic properties of a compound, potentially enhancing its efficacy and safety profile.

Upstream product

• 317-20-4 7-fluoro-1H-indole-2,3-dione 
• 825-22-9 3-fluoroanthranilic acid 
• 2592-95-2 benzotriazol-1-ol 

Downstream Products

• 1295570-35-2 C₇H₆BrFN₂O 

Relevant articles and documents

Acid-Catalyzed Synthesis of Isatoic Anhydride-8-Secondary Amides Enables IASA Transformations for Medicinal Chemistry

Quinazolin-dione-N-3-alklyl derivatives are the core scaffolds for several categories of bioactive small molecules, but current synthetic methods are costly, involve environmental hazards, and are not uniformly scalable. Here, we report an inexpensive, flexible, and scalable method for the one-pot synthesis of substituted quinazolin-dione-N-3-alkyls (isomers of isatoic-8-secondary amides (IASAs)) from isatin that take advantage of in situ capture of imidic acid under acidic conditions. We further show that this method can be used for the synthesis of a wide variety of derivatives with medicinal uses.

Tunable Electrosynthesis of Anthranilic Acid Derivatives via a C-C Bond Cleavage of Isatins

A facile and direct electrocatalytic C-C bond cleavage/functionalization reaction of isatins was developed. With isatins as the amino-attached C1 sources, a variety of aminobenzoates, and aminobenzamides were synthesized in moderate to good yields under mild conditions.

Oxidative ring-opening of isatins for the synthesis of 2-aminobenzamides and 2-aminobenzoates

An efficient and practical isatin-based oxidative domino protocol has been developed for the facile synthesis of 2-aminobenzamides and 2-aminobenzoates. The robust nature of this reaction system is reflected by accessible starting materials, room temperature and high-yield gram-scale synthesis.

NITROGEN CONTAINING BICYCLIC DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS

The present invention relates to new compounds of formula (I): showing great affinity and activity towards the subunit α2δ of voltage-gated calcium channels (VGCC), especially the α2δ-1 subunit of voltage-gated calcium channels or dual activity towards the subunit α2δ of voltage-gated calcium channels (VGCC), especially the α2δ-1 subunit of voltage-gated calcium channels, and the noradrenaline transporter (NET).

POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS

The present invention is related to a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound represented by the following structural formula: The present invention is also related a method of treating a subject with a disease which can be ameliorated by inhibition of poly(ADP-ribose)polymerase (PARP). The definitions of the variables are provided herein.

QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF

Provided herein are quinazoline compounds for treatment of JAK kinase mediated diseases, including JAK2 kinase-, JAK3 kinase- or TYK2 kinase-mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.

Synthesis and biological evaluation of 4-quinazolinones as Rho kinase inhibitors

Rho kinase (ROCK) is an attractive therapeutic target for various diseases including glaucoma, hypertension, and spinal cord injury. Herein, we report the development of a series of ROCK-II inhibitors based on 4-quinazolinone and quinazoline scaffolds. SAR studies at three positions of the quinazoline core led to the identification of analogs with high potency against ROCK-II and good selectivity over protein kinase A (PKA).